Inactive Instrument

Vyant Bio, Inc. Stock

VYNT

US92942V2088

Latest news about Vyant Bio, Inc.

Vyant Bio, Inc. Estimates Liquidation Payments to its Shareholders	11-10	CI
Vyant Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
Vyant Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-07-31	CI
AxoSim, Inc. entered into an agreement to acquire microBrain?-associated assets from Vyant Bio, Inc. for $3.5 million.	23-07-16	CI
Vyant Bio, Inc.(NasdaqCM:VYNT) dropped from S&P TMI Index	23-05-17	CI
Vyant Bio, Inc.(OTCPK:VYNT) dropped from NASDAQ Composite Index	23-05-12	CI
Top Midday Decliners	23-04-25	MT
Vyant Bio to Voluntarily Delist From Nasdaq, Deregister From SEC; Shares Slide After Hours	23-04-24	MT
Vyant Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Vyant Bio, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
HC Wainwright Downgrades Vyant Bio to Neutral From Buy	23-02-03	MT
Vyant Bio CEO to Step Down, Successor Named; Cuts Staff as Strategic Review Process Gets Underway	23-02-03	MT
Vyant Bio, Inc. Announces Executive Changes	23-02-03	CI
Vyant Bio, Inc. Announces CEO Changes	23-02-03	CI
Strong Labor Data in Spotlight After Hawkish Fed Minutes, US Equity Futures Turned Lower Ahead of Opening Bell	23-01-05	MT

More news

Analyst Recommendations on Vyant Bio, Inc.

HC Wainwright Downgrades Vyant Bio to Neutral From Buy	23-02-03	MT
Ascendiant Starts Vyant Bio at Buy With $1.88 Price Target	22-10-04	MT
HC Wainwright Trims Vyant Bio's Price Target to $3 From $4, Buy Rating Kept	22-05-17	MT
HC Wainwright Adjusts Vyant Bio's Price Target to $4 from $5, Keeps Buy Rating	22-03-08	MT
VYANT BIO : HC Wainwright Starts Vyant Bio at Buy with $5 Price Target	21-10-06	MT

More recommendations

Press releases Vyant Bio, Inc.

Vyant Bio Announces Last Day of Trading on Nasdaq and Filing of Form 15 for Voluntary Nasdaq Delisting and SEC Deregistration	23-05-12	AQ
VYANT BIO, INC. : Change in Directors or Principal Officers (form 8-K)	23-05-10	AQ
Vyant Bio Announces Filing of Form 25 for Voluntary Nasdaq Delisting and SEC Deregistration	23-05-04	AQ
VYANT BIO, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits (form 8-K)	23-04-24	AQ
Vyant Bio Announces Voluntary Nasdaq Delisting and SEC Deregistration	23-04-24	AQ

More press releases

Managers and Directors - Vyant Bio, Inc.

Managers	Title	Age	Since
Andrew LaFrence CEO	Chief Executive Officer	61	19-07-31
Jay Roberts BRD	Director/Board Member	-	18-03-31
Yung Ping Yeh BRD	Director/Board Member	48	21-02-28

Members of the board	Title	Age	Since
Geoffrey Harris BRD	Director/Board Member	61	13-12-31
Joanna Horobin BRD	Director/Board Member	69	20-12-31
R. Fletcher CHM	Chairman	78	21-03-29

More insiders

Vyant Bio, Inc. has no continuing operating activities other than the winddown and closure of its business. The Company is seeking to obtain its shareholdersâ approval for the voluntary liquidation and dissolution of the Company, pursuant to a plan of liquidation and dissolution.

Sector

Investment Holding Companies

More about the company

Sector Shell Companies

	1st Jan change	Capi.
TRUMP MEDIA & TECHNOLOGY GROUP CORP.	+137.37%	5.68B
SCREAMING EAGLE ACQUISITION CORP.	+1.89%	1.01B
CHURCHILL CAPITAL CORP VII	+2.19%	982M
APPLE ISPORTS GROUP, INC.	+41.91%	872M
PERELLA WEINBERG PARTNERS	+25.27%	819M
ARES ACQUISITION CORPORATION II	+1.68%	663M
E7 GROUP	+0.54%	610M
DA ZHONG TRADING GROUP HOLDING COMPANY	-.--%	600M
ALTC ACQUISITION CORP.	+21.31%	552M